Safety, tolerability and pharmacokinetics of multiple once-daily dosing of oral semaglutide in healthy males and in males with type 2 diabetes

被引：0
|
作者：
Granhall, C. [1 ]
Donsmark, M. [1 ]
Golor, G. [2 ]
Sondergaard, F. L. [1 ]
Thomsen, M. [1 ]
机构：
[1] Novo Nordisk, Soborg, Denmark
[2] Parexel Int, Berlin, Germany
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
790
引用
收藏
页码：S362 / S363
页数：2
相关论文
共 50 条
  • [31] STEADY-STATE PHARMACOKINETICS AND TOLERABILITY OF ONCE-DAILY AND TWICE-DAILY REGIMENS OF ESLICARBAZEPINE ACETATE IN HEALTHY VOLUNTEERS
    Vaz-Da-Silva, M.
    Falcao, A.
    Nunes, T.
    Almeida, L.
    Soares-Da-Silva, P.
    EPILEPSIA, 2012, 53 : 119 - 119
  • [32] Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib
    Begg, M.
    Wilson, R.
    Hamblin, J. N.
    Montembault, M.
    Green, J.
    Deans, A.
    Amour, A.
    Worsley, S.
    Fantom, K.
    Cui, Y.
    Dear, G.
    Ahmad, S.
    Kielkowska, A.
    Clark, J.
    Boyce, M.
    Cahn, A.
    Hessel, E. M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 369 (03): : 337 - 344
  • [33] The effect of multiple oral administration of esaxerenone on the pharmacokinetics of midazolam in healthy japanese males
    Furuie, H.
    Toyama, K.
    Okuda, Y.
    Kuroda, K.
    Shimizu, T.
    Kato, M.
    Ishizuka, H.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S38 - S38
  • [34] Pharmacokinetics of nevirapine: Once-daily versus twice-daily dosing in the 2NN study
    Kappelhoff, BS
    Huitema, ADR
    van Leth, F
    Robinson, PA
    MacGregor, TR
    Lange, JMA
    Beijnen, JH
    HIV CLINICAL TRIALS, 2005, 6 (05): : 254 - 261
  • [35] Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily β2-agonist bronchodilator, in subjects with COPD
    Pascoe, S.
    Reynolds, C.
    Pleskow, W.
    Perry, S.
    Hmissi, A.
    Kaiser, G.
    Brookman, L.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (02) : 153 - 161
  • [36] Detemir as a once-daily basal insulin in type 2 diabetes
    Nelson, Scott E.
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2011, 3 : 27 - 37
  • [37] Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
    Charlotte Granhall
    Morten Donsmark
    Thalia M. Blicher
    Georg Golor
    Flemming L. Søndergaard
    Mette Thomsen
    Tine A. Bækdal
    Clinical Pharmacokinetics, 2019, 58 : 781 - 791
  • [38] Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects
    Thompson, M
    DeJesus, E
    Richmond, G
    Wheeler, D
    Flaherty, J
    Piliero, P
    True, A
    Chiu, YY
    Zhang, Y
    McFalls, E
    Miralles, GD
    Patel, IH
    AIDS, 2006, 20 (03) : 397 - 404
  • [39] Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
    Granhall, Charlotte
    Donsmark, Morten
    Blicher, Thalia M.
    Golor, Georg
    Sondergaard, Flemming L.
    Thomsen, Mette
    Baekdal, Tine A.
    CLINICAL PHARMACOKINETICS, 2019, 58 (06) : 781 - 791
  • [40] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-875, a Novel GPR40 Agonist, Following Once-Daily Oral Administration for 2 Weeks in Type 2 Diabetic Patients
    Leifke, Eckhard
    Wu, Jingtao
    Viswanathan, Prabhakar
    Kipnes, Mark S.
    Vakilynejad, Majid
    DIABETES, 2011, 60 : A114 - A115
12345